Skip to content
drillr.ai
Sign up

HIMS

Hims & Hers Health, Inc.

NYSE · Healthcare · Medical - Equipment & Services · US

$27.99
+0.36%
Ask drillr

  • Sep 17, 2026, 20:30 UTC

    A securities fraud class action lawsuit, Velanki v. Hims & Hers Health, Inc., was filed against Hims & Hers Health in the U.S. District Court for the Northern District of California over alleged misstatements about its privacy practices, with a November 2, 2026 deadline for lead plaintiff status.

    Source:

  • Sep 15, 2026, 22:45 UTC

    Hims & Hers Health, Inc. (HIMS) closed at $27.93, down 3.07% from the previous trading day, falling more steeply than the broader market.

    Source:

  • Sep 14, 2026, 19:21 UTC

    Hims & Hers Health Inc stock rose 6.6% to trade at $29.34.

    Source:

  • Sep 14, 2026, 17:30 UTC

    Robbins LLP announced a class action filed on behalf of investors who purchased Hims & Hers Health, Inc. securities between August 4, 2025 and July 29, 2026, alleging the company shared customers' protected information with advertising platforms and engaged in deceptive advertising practices.

    Source:

  • Sep 10, 2026, 20:45 UTC

    Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Hims & Hers Health, Inc. on behalf of investors who acquired its securities between August 4, 2025 and July 29, 2026, with a lead plaintiff deadline of November 2, 2026.

    Source:

  • Sep 4, 2026, 16:01 UTC

    A class action lawsuit was filed against Hims & Hers Health, Inc. alleging that the company made materially false and misleading statements during the Class Period, causing investor harm.

    Source:

  • Sep 3, 2026, 20:00 UTC

    A class action lawsuit was filed against Hims & Hers Health, Inc. on behalf of investors who purchased its securities between August 4, 2025 and July 29, 2026.

    Source:

  • Aug 31, 2026, 18:56 UTC

    Hims & Hers began offering branded GLP-1 weight-loss drugs and men's health treatments in Australia on Monday, expanding its international business.

    Source:

  • Aug 24, 2026, 17:00 UTC

    BBB National Programs' National Advertising Division ruled on a challenge by Kenvue Inc., finding that Hims & Hers Health, Inc. had support for its comparative efficacy claim but recommending modification or discontinuance of other advertising claims.

    Source:

  • Aug 24, 2026, 16:45 UTC

    Hims & Hers Health received a warning from Visa due to excessive customer disputes over its weight-loss drug subscription service, leading to its inclusion in Visa's Acquirer Monitoring Program (VAMP).

    Source:

  • Aug 11, 2026, 13:45 UTC

    Hims & Hers Health announced plans to enter the peptide market within the year to capture demand in the rapidly growing healthcare market.

    Source:

  • Aug 11, 2026, 11:21 UTC

    Hims & Hers Health's shares fell nearly 7% in premarket trading on Tuesday, reflecting investor concerns over shrinking profit margins.

    Source:

  • Aug 10, 2026, 20:05 UTC

    Hims & Hers Health, Inc. announced its financial results for the second quarter ended June 30, 2026.

    Source:

  • Jul 24, 2026, 03:40 UTC

    An FDA advisory panel voted to recommend easing restrictions on four peptides (BPC-157, KPV, TB-500, MOTS-C), potentially expanding the market for telehealth firms like Hims & Hers Health.

    Source:

  • Jul 17, 2026, 20:17 UTC

    Hims & Hers Health announced that Chief Accounting Officer Irene Becklund will depart the company effective October 9, 2026.

    Source:

  • Jul 8, 2026, 12:34 UTC

    Hims & Hers Health acquired Eucalyptus for $1.15 billion, adding 850,000 customers and approximately $450 million of ARR across eight international markets.

    Source:

  • Jul 8, 2026, 12:34 UTC

    Hims & Hers Health secured a $400 million receivables facility from JPMorgan to improve financial flexibility.

    Source:

  • Jul 1, 2026, 18:15 UTC

    Hims & Hers Health shares surged 9% on Wednesday.

    Source:

  • Jul 1, 2026, 00:00 UTC

    Hims & Hers Health, Inc. entered into a Master Receivables Purchase Agreement with JPMorgan Chase Bank, N.A., establishing a $400 million uncommitted facility for the purchase of eligible receivables, and amended its existing revolving credit agreement to permit this transaction.

  • Jun 24, 2026, 23:59 UTC

    Hims & Hers Health completed its acquisition of Eucalyptus on June 2.

    Source:

  • Jun 4, 2026, 13:00 UTC

    Hims & Hers Health appointed Dr. Anant Vinjamoori as Chief Medical Officer of the Hims brand.

    Source:

  • Jun 2, 2026, 09:00 UTC

    Hims & Hers Health, Inc. completed its acquisition of Eucalyptus, the parent company of Juniper, expanding its weight management care in Germany.

    Source:

  • Jun 2, 2026, 00:00 UTC

    Hims & Hers Health, Inc. amended its existing revolving credit facility on May 29, 2026, to facilitate its acquisition of Eucalyptus, increasing allowable investments in non-loan party subsidiaries and adding joinder obligations for material foreign subsidiaries.

  • May 21, 2026, 00:00 UTC

    Hims & Hers Health, Inc. issued $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032, comprising $350.0 million initial principal and a $52.5 million option to purchase additional notes, with conversion into Class A Common Stock at an initial rate of 33.8590 shares per $1,000 principal amount.